For centuries, genetics study has been the core benchmark for patient’s treatment. The study of genetic variation in patients mainly contributes to the final diagnosis. With a correct diagnosis, comes the right treatment. It is, therefore, vital for physicians to understand genetic mutation while administering treatment. That is why Dr. Clay Siegall of Seattle Genetics is cheered for his massive contribution to the genetic study. The co-founder of Seattle Genetics started his career in the company in 1998. As the serving president and chief executive officer, Clay has always chaired the board in decision making. With his leadership skills, Clay Siegall has seen Seattle Genetics develop innovative practices towards disease treatment.
Recently, the company announced its position in generating antibody conjugates. These antibodies are known as ADCs. After the development of ADCs, he pushed for the treatment to be certified by FDA in 2011. This was the first FDA approval of ADCs. Clay’s leadership at Seattle Genetics extends to the collaboration of the company with Takeda Pharmaceuticals. With the partnership, Seattle Genetics has become prominent. ADC is currently approved in over 65 countries. Clay’s leadership at Seattle Genetics is vastly advancing the company’s distribution of ADCs.
Clay Siegall is an executive scientist and researcher. He focuses his studies on genetic mutation and assimilation. The alumnus of George Washington University was appointed a board member of Mirna Therapeutics in 2013. This was because of his profound commitment to finding treatment through genetic study. While forming Seattle Genetics in 1998, his core agenda was to provide treatment for cancers like lymphoma and other diseases. He has ensured this by partnering with major stakeholders in disease control centers to develop treatment solutions.
Additionally, his experience roots from the vast experience in previous institutions. He worked at Bristol-Myers Squibb Pharmaceuticals from 1991 to 1997. He also worked at the National Cancer Research Institute and National Health Institute from 1988 to 1991. He is a member of the board in several companies including Alder BioPharmaceuticals, Ultragenyx Pharmaceutical and Washington Roundtable. It is evident that Clay Siegall is committed to finding treatment solutions for cancer and other diseases through genetic study.